Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jessica Petry

Internal Medicine Lafayette, LA Medical Doctor

NPI 1083000384 CMS profile 2787637

206 Energy Parkway, Lafayette, LA 70508

Open in the dashboard

General payments

$3,352

216 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Petry of Lafayette, LA is reported in the CMS Open Payments database as having received $3,352 across 216 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $445 26
2024 General $708 40
2023 General $567 37
2022 General $595 40
2021 General $275 18
2020 General $259 19
2019 General $503 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Petry
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jessica Petry were reported at $445. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jessica Petry Internal Medicine median Middle half National median
2019 $503 $159 $48–$570 $163
2020 $259 $119 $33–$402 $114
2021 $275 $135 $37–$521 $132
2022 $595 $141 $42–$496 $149
2023 $567 $149 $45–$519 $160
2024 $708 $154 $47–$537 $164
2025 $445 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $462 30 payments
  2. Lilly USA, LLC $425 32 payments
  3. Novo Nordisk Inc $393 27 payments
  4. Amgen Inc. $386 25 payments
  5. Pfizer Inc. $262 14 payments
  6. AbbVie, Inc. $178 10 payments
  7. GlaxoSmithKline, LLC. $157 9 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $125 8 payments
  9. Novartis Pharmaceuticals Corporation $109 7 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $93 6 payments
  11. Other $764 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,352 216 payments
Products named General payments · program years 2019–2025
  1. Ozempic $261 19 payments
  2. FARXIGA $246 15 payments
  3. MOUNJARO $226 14 payments
  4. AIRSUPRA $186 11 payments
  5. Prolia $182 12 payments
  6. RYBELSUS $166 12 payments
  7. Repatha $156 10 payments
  8. EVENITY $152 10 payments
  9. SHINGRIX $142 8 payments
  10. ELIQUIS $141 7 payments
  11. Other $2,841 190 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 130 drugs

Part D claims

6,268

Median for Internal Medicine: 777

Drug cost

$612,172

Median for Internal Medicine: $73,373

Branded share of claims

23.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 106 $133,939
Ozempic Semaglutide Brand 92 $127,176
Jardiance Empagliflozin Brand 41 $53,836
Eliquis Apixaban Brand 39 $36,041
Xifaxan Rifaximin Brand 11 $35,587
Trulicity Dulaglutide Brand 11 $21,840
Linzess Linaclotide Brand 19 $21,012
Xarelto Rivaroxaban Brand 11 $17,629
Januvia Sitagliptin Phosphate Brand 25 $17,201
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 28 $12,997

The 10 drugs with the highest cost, of 130 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$157,222

Of which drugs: $9,407

Medicare patients

405

Average age 75

Services billed

2,404

295 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Ischemic heart disease 36%
Depression 33%
Diabetes 28%
Chronic kidney disease 22%
Atrial fibrillation 21%
Osteoporosis 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 75 75 $5,953
Pcv20 vaccine im 90677 Office 12 12 $3,185

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $79
$79 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $76
$76 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $60
$60 — —
ELIQUIS
  • PFIZER INC. $59
$59 39 —
MOUNJARO
  • Lilly USA, LLC $44
$44 106 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

216 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record